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Abstract 
 
 The lymphatic vascular system maintains tissue fluid homeostasis, helps mediate 
afferent immune responses and promotes cancer metastasis. To address the role microRNAs 
(miRNAs) play in the development and function of lymphatic vascular system, we defined the 
in vitro miRNA expression profiles of primary human lymphatic endothelial cells (LECs) and 
blood vascular endothelial cells (BVECs) and identified 4 BVEC-signature and 2 LEC-
signature miRNAs. Their vascular lineage-specific expression patterns were confirmed in 
vivo by quantitative real-time PCR (qRT-PCR) and in situ hybridization (ISH). Functional 
characterization of the BVEC-signature miRNA, miR-31, identified a novel BVEC-specific 
post-transcriptional regulatory mechanism that inhibits the expression of lymphatic-specific 
transcripts in vitro. We demonstrate that suppression of lymphatic differentiation is partially 
mediated via direct repression of PROX1, a transcription factor that functions as a master 
regulator of lymphatic lineage-specific differentiation. Finally, in vivo studies in Xenopus and 
zebrafish demonstrated that gain-of-miR-31 function impaired venous sprouting and 
lymphatic vascular development. Thus, highlighting the importance of miR-31 as a negative 
regulator of lymphatic development. Collectively, our findings identify miR-31 is a potent 
regulator of vascular lineage-specific differentiation and development in vertebrates.  
 
 
 
 
 
 
 
 
Key words: miRNA post-transcriptional regulation, vascular development, 
lymphangiogenesis, PROX1, miR-31 
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Introduction 
 
 Vertebrates have developed two parallel, but structurally and functionally distinct, 
vascular systems: the blood and lymphatic vascular systems(1, 7). The lymphatic vascular 
system controls tissue fluid homeostasis, absorbs lipids and fat-soluble vitamins from the 
intestine, and mediates afferent immune responses by transporting lymphocytes and antigen-
presenting cells to regional lymph nodes(1, 7). In addition, malignant cancers can induce 
lymphatic vessel activation and growth (lymphangiogenesis) within primary tumors and 
draining lymph nodes, which enhances cancer metastasis to draining lymph nodes and 
beyond(1, 22). These findings have fueled a surge of studies aimed at defining the molecular 
characteristics and functional activities of lymphatic vessels, and identifying molecules that 
regulate lymphangiogenesis.  
 Genomic and proteomic studies have identified novel molecular markers and growth 
factors for lymphatic vessels(2, 23, 48, 52). Genetic mouse models have characterized the 
transcription factors PROX1 and SOX18 as master regulators of lymphatic vascular 
development and differentiation in vivo(12, 56, 65). These studies indicate that SOX18 
expression in a subset of cardinal vein endothelial cells initiates lymphatic vascular 
development by inducing PROX1 expression(12). The resulting lymphatic vascular 
progenitor cells bud off and migrate away from the cardinal vein and form primitive lymph 
sacs, which subsequently develop into functional lymphatics(12, 56). PROX1 and SOX18 
expression in cultured BVECs triggers these cells to adopt lymphatic-specific molecular and 
phenotypic characteristics(12, 26, 48). Conversely, PROX1 knockdown in LECs inhibits the 
expression of LEC-signature genes and triggers BVEC-signature gene expression(44 and Shin 
et al., manuscript in preparation). Despite these advances, a detailed understanding of the 
mechanisms controlling lymphatic vascular development and cell type-specific differentiation 
remains elusive. 
 A potentially crucial aspect of lymphatic vascular biology has remained unexplored 
to date: the role of miRNA-guided post-transcriptional regulation. miRNAs are genomically 
encoded, 19-24 nucleotide non-coding RNAs that regulate the flow of genetic information by 
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limiting protein synthesis(10). This regulation is brought about when mature miRNAs, loaded 
in the RNA-induced silencing complex (RISC), base-pair with semi-complementary sites 
within the 3’ untranslated region (3’UTR) of target mRNAs. Once base-paired with its target, 
the miRNA represses translation and/or induces mRNA degradation(10). Consequently, 
miRNAs act as novel and potent regulators of the genome. This notion is underscored by 
recent studies defining critical roles for miRNAs in embryonic development, cell 
proliferation, cell cycle progression, differentiation, and apoptosis, as well as their 
contribution to the etiology of several diseases(10, 46, 68).  
Interestingly, functional roles for miRNAs in blood vascular development have 
recently been defined. Down-regulation of the miRNA processing enzymes Dicer and Drosha 
have been reported to impair angiogenesis(11, 59). Moreover, a few miRNAs have been 
shown to affect human umbilical vein endothelial cell (HUVEC) migration and proliferation 
in vitro, regulate nitric oxide synthase expression, promote tumor angiogenesis, control 
vascular inflammation, and directly contribute to numerous vascular phenotypes(11, 59). 
 In the study presented here, we identified and addressed the functional relevance of 
vascular lineage-specific miRNAs. We first defined the miRNA expression profiles of 
primary human LECs and BVECs and, consequently, identified 4 BVEC- and 2 LEC-
signature miRNAs. Their vascular lineage-specific expression was confirmed in normal 
tissues by qRT-PCR analysis of ex vivo isolated murine LECs and BVECs and by ISH.  
Interestingly, our findings have further classified the widely-expressed(38), metastasis-
associated(63, 64) miRNA, miR-31, as a BVEC-signature miRNA.  In vitro functional 
analysis of miR-31 demonstrated that this miRNA inhibits lymphatic lineage-specific 
differentiation in BVECs by repressing lymphatic-specific transcript levels. These effects are, 
in part, due to direct post-transcriptional repression of Prox1, a master regulator of lymphatic 
development. Finally, in vivo gain-of-function studies in Xenopus and zebrafish embryos 
established that overexpression of miR-31 impaired lymphatic development and reduced 
venous sprouting. Taken together, these findings indicate that miR-31 plays a pivotal role in 
regulating lineage-specific differentiation within the developing vasculature of vertebrates. 
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Materials and Methods 
Cell Culture 
 Primary human dermal microvascular LECs and BVECs were isolated from neonatal 
human foreskins and cultured as previously described(23). cLECs and HUVECs were 
purchased from Cambrex (Verviers, Belgium). Human IMR91 dermal fibroblasts (hdFBs) 
were obtained from the National Institute on Aging, Bethesda, MD, USA. The immortalized 
human epidermal keratinocyte line HaCaT was provided by Dr. Norbert Fusenig, German 
Cancer Research Center, Heidelberg, Germany(4). Cells, except hdFBs, were propagated in 
supplemented endothelial cell basal medium (EBM; Cambrex) as described(23). hdFBs were 
propagated in D-MEM (Dulbecco’s modified eagle medium) supplemented as described 
above and transferred 12 hrs prior to total RNA isolation to EBM supplemented as described 
above. Primary cells were used at passage 6. 
 
In vitro miRNA expression profiling 
 The TaqMan microRNA Assays Human Panel Early Access Kit (Applied 
Biosystems, Foster City, CA), containing 157 individual human TaqMan microRNA assays, 
was used for qRT-PCR miRNA expression profiling(5). Total RNA was isolated from 
biological replicates of 80-90% confluent 10-cm tissue culture dishes using the mirVana 
miRNA isolation kit (Ambion, Austin, TX). Reverse transcription reactions were performed 
using 2 ng of total RNA and the microRNA Reverse Transcription kit (Applied Biosystems). 
miRNA expression levels of technical duplicates were determined using a 7900HT Fast Real-
Time PCR System (Applied Biosystems) and comparative threshold cycle (Ct) values 
acquired after 40 cycles using SDS 2.2 software (Applied Biosystems). TaqMan microRNA 
assays (Applied Biosystems) for hsa-miR-31, hsa-miR-137, hsa-miR-99a, hsa-miR-125b, hsa-
miR-95, hsa-miR-326 and human RNU48 were used to confirm lineage-specific expression.  
For analysis, detection thresholds were set to 0.04 units of fluorescent intensity and when a 
miRNA Ct value was undetermined in both technical replicates, Ct values of 41 were 
assigned. Datasets were normalized relative to let-7a and miR-16 using the formula: 
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AveCtNORM=AveCtmiRNA–(AveCtlet-7a/miR-16–24), where AveCtlet-7a/miR-16 is the combined 
average Ct value for let-7a and miR-16 from each 96-well plate. RNU48 or sno234 were used 
to normalize the individual TaqMan microRNA assay datasets using the formula: 
AveCtNORM=AveCtmiRNA–(AveCtRNU48 or sno234–25), where AveCtRNU48 or sno234 is the mean 
RNU48 or sno234 Ct value (n=3). Relative abundances for LECs and BVECs were calculated 
from log2 ratios. P-values were calculated using a two-tailed Student’s t-test. 
 
FACS isolation of endothelial cells from mouse colons 
 Animal experiments in mice were approved by the Kantonales Veterinäramt Zürich. 
Colons were excised from sacrificed female FVB mice (Charles River, Sulzbach, Germany; 
12-16 weeks old; n=8), opened longitudinally, washed in cold PBS and placed in 1 mM DTT. 
Mucus was gently removed by scraping. Small tissue pieces were digested with 8 mg/ml 
collagenase IV (Invitrogen, Carlsbad, CA), 0.5 mg/ml DNaseI (Roche, Rotkreuz, 
Switzerland) and 5 mM CaCl2 in PBS at 37 0C for 15 min. After passing through a 70 µm cell 
strainer (BD Biosciences, Franklin Lakes, NJ), the resulting cell suspensions were centrifuged 
at 500 g for 10 min and resuspended in 2% FBS-supplemented PBS, containing 1 mM EDTA.  
 Antibodies used for FACS sorting were: allophycocyanin (APC)-conjugated rat anti-
mouse CD31 (BD Biosciences Pharmingen, San Diego, CA), fluorescein isothiocyanate 
(FITC)–conjugated rat anti-mouse CD45.2 (BD Biosciences), hamster anti-mouse podoplanin 
(clone 8.1.1; Developmental Studies Hybridoma Bank, Iowa City, IA), anti-hamster 
phycoerythrin (PE) (CALTAG/Invitrogen) and isotype control antibodies. FACS sorting was 
performed using a FACSAria and the FACSDiva software (BD Biosciences). Cells were 
lysed by sorting directly into RLT Plus lysis buffer (Qiagen, Hilden, Germany) containing β-
mercaptoethanol. Total RNA was extracted from LECs (CD45–CD31+podoplanin-) and 
BVECs (CD45–CD31+podoplanin+), using the RNeasy Plus Micro kit (Qiagen, Hilden, 
Germany). For miRNA expression analyses, 6 ng of total RNA and TaqMan miRNA assays 
for mmu-miR-31, mmu-miR-326, hsa-miR-137, hsa-miR-99a, hsa-miR-125b and mouse 
sno234 were used. 
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In Situ hybridization and immunofluorescence staining 
 miR-31 in situ hybridization and Lyve-1/CD31 immunofluorescence were  performed 
on 20 µm serial frozen sections of mouse colons obtained from female FVB mice. In situ 
hybridization for mouse miR-31 was performed using digoxigenin (DIG)-labeled locked 
nucleic acid (LNA)-modified detection probes (mmu-miR-31, product # 39153-00; 
hsa/mmu/rno-U6, positive control, # 99002-00); sense miR-159, negative control, # 99003-
00; Exiqon, Vedbæk, Denmark) and the formaldehyde/EDC fixation miRNA ISH 
protocol(47). Briefly, the LNA-modified detection probes were labeled with Digoxigenin 
(DIG) using the DIG Oligonucleotide Tailing Kit (Roche, Basel, Switzerland) according to 
the manufacturer’s instructions.  Tissue sections were fixed in 4% formaldehyde/Tris buffered 
saline (TBS) for 10 min and then in EDC solution(47) for 1.5 hours.  The sections were 
acetylated in 1% triethanolamine/0.25% acetic anhydride, washed and prehybridized in 
hybridization buffer(47) for 1 hour at 53°C. The colon tissue sections were hybridized with 
4µM DIG-labeled detection probes overnight at 56°C for miR-31 and 53°C for the controls.  
Following post-hybridization washing and blocking, the slides were probed with alkaline 
phosphatase conjugated anti-DIG Fab fragments (Roche).  They were then washed in TNT 
buffer (100 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Tween 20) and in AP Buffer (100 
mM Tris-HCl pH 9.5, 100 mM NaCl, 50 mM MgCl2).  Color developed was performed in 
Developer solution (AP Buffer with 0.175 mg/mL BCIP, 0.45 mg/ml NBT and 2mM 
levamisol). All incubations and washing steps were performed at room temperature unless 
otherwise indicated. 
 Immunofluorescence stains were performed as described(25, 35) using a rabbit 
polyclonal antibody against mouse Lyve-1 (AngioBio, Del Mar, CA), a monoclonal rat 
antibody against mouse CD31 (BD Biosciences) and corresponding secondary antibodies 
labeled with AlexaFluor488 or AlexaFluor594 (Molecular Probes). Sections were examined 
on an Axioskop2 microscope (Carl Zeiss, Feldbach, Switzerland), and images were captured 
at 2.5x (Plan-NEOFLUAR 2.5x/0.075 NA) and 20x (Plan-NEOFLUAR 20x/0.50 Ph2) 
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 9 
magnification with an AxioCam MRm digital camera (Zeiss). Brightfield and fluorescent 
channel image acquisition was accomplished using Axio Vision4.4 software (Zeiss). Adobe 
Photoshop CS3 (Adobe Systems, San Jose, CA) was used to adjust image brightness.  
 
Microarray analyses 
 All transfections were carried out using the Basic Nucleofector Kit for primary 
mammalian endothelial cells (Amaxa AG, Cologne, Germany). 500,000 LECs were 
transfected with 2 µM Pre-miR-31 or Pre-miR-Neg molecules(30) in biological duplicate and 
total RNA isolated using the mirVana isolation kit 48 hours post-transfection. The 
transcriptome profiles of these cells were defined using the Applied Biosystems Human 
Genome Survey Microarray v2.0 as described(54). Briefly, dioxigenin-UTP-labeled cRNA 
was generated from 1.5 µg of total RNA using the NanoAmp RT-IVT Labeling Kit (Applied 
Biosystems). 20 µg cRNA were fragmented and hybridized to the microarrays using the 
Applied Biosystems Chemiluminescence Detection Kit. Signal detection, image acquisition 
and initial analyses were performed using the Applied Biosystems 1700 Chemiluminescent 
Microarray Analyzer. Microarray data are accessible at http://www.ncbi.nlm.nih.gov/geo/ 
(GSE16908). 
 Raw data were normalized using Quantile normalization available from 
R/Bioconductor(14). Present calls were defined based on average signal-to-noise ratios (S/N 
ratio) >3 and quality (error) values <5,000(54). Feature signal intensities were converted to 
log2 values. miR-31-repressed genes were identified based on present calls in both Pre-miR-
Neg arrays, log2(Pre31/PreNeg) ≤-0.59 and p-values <0.05, while miR-31-induced genes 
were present in both Pre-miR-31 arrays, had log2(Pre31/PreNeg) ≥0.59 and p-values <0.05. P-
values were calculated using empirical Bayes statistics for differential expression(55). 
 
mRNA quantitative RT-PCR analyses 
 To confirm the microarray data, the mRNA expression levels of selected candidate 
miR-31-regulated LEC- and BVEC-signature genes were analyzed in triplicate by 
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quantitative real-time RT-PCR (qRT-PCR) using dual-labeled TaqMan Gene Expression 
Assays for TIMP3 (Assay ID: Hs00165951_g1), PPP1R9A (Hs01044146_m1), HOXD10 
(Hs00157974_m1), EDNRB (Hs00240752_m1), PROX1 (Hs00160463_m1), NRCAM 
(Hs00170554_m1), SELE (Hs00950401_m1), ICAM1 (Hs99999152_m1), MMP1 
(Hs00899658_m1), RGS4 (Hs00194501_m1), NRG1 (Hs00247620_m1) and LOC554202 
(Hs01007340_m1; all from Applied Biosystems). The probe and primers for LYVE-1 were as 
described(23). 25 ng of cDNA, generated using the High Capacity cDNA Archive Kit 
(Applied Biosystems) were used. Each reaction was normalized to β-actin expression(54). 
 
Detailed analysis of PROX1 mRNA and protein levels 
 To further characterized miR-31 regulation of PROX1, 500,000 LECs were transfected 
with 2 µM or 4 µM Pre-miR-31 (n=4) or Pre-miR-Neg (n=4) molecules, or 4 µM Anti-miR-
31 (n=2) or Anti-miR-Neg (n=2) molecules(6).   Total RNA and whole cell protein lysates 
were isolated using the mirVana PARIS kit 48 hours post-transfection.  qRT-PCR analysis of 
PROX1 mRNA was preformed as described in the main text.   
 Northern blot analyses were performed on 1 µg total RNA.  PROX1 mRNA was 
detected using purified PROX1 3’UTR γ32ATP end-labeled probes generated from a NotI-
linearized human PROX1 3’UTR plasmid (YH1551; provided by Dr. Young Kwon Hong, 
University of Southern California, Los Angeles, CA).  The membrane was then stripped and 
β-actin detected using γ32ATP end-labeled human β-actin oligonucleotides (5’-
GTGAGGATCTTCATGAGGTAGTCAGTCAGGT-3’). 
 For western blotting, 25 µg of the protein lysates were resolved by SDS-PAGE and 
transferred to nitrocellulose membranes. Membranes were probed with rabbit polyclonal anti-
human PROX1 (RELIATech, Braunschweig, Germany) and mouse monoclonal anti-human 
β-actin antibodies (Sigma-Aldrich), detected using horseradish peroxidase (HRP)-conjugated 
secondary antibodies and standard chemiluminescence(54).  QuantityOne software (Bio-Rad) 
was used to semi-quantitatively analyze the amounts of PROX1 protein relative to β-actin in 
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each sample. Pre-miR-31 and Pre-miR-Neg PROX1 signal volume averages and standard 
deviations of the mean were calculated from these normalized values (n=4). P-values were 
calculated using a two-tailed Student’s t-test. 
DNA Constructs 
 pMIR-Luci/miR31BS and psiCHECK-2/miR31BS contain perfect match hsa-miR-31 
binding sites (miR31BS). pMIR-Luci/miR31BS was generated by cloning annealed miR-
31BS sense (5’– AGCTTGCTGAGCGGCAAGATGCTGGCATAGCTGA–3’) and antisense 
(5’– CTAGTCAGCTATGCCAGCATCTTGCCGCTCAGCA–3’) oligonucleotides as into 
the HindIII and SpeI restriction sites of the pMIR-REPORT Luciferase vector(Cheng et al, 
2005). psiCHECK-2/miR31BS was constructed by ligating annealed miR31BS/F and 
miR31BS/R oligonucleotides (Supplementary Table 1) into the XhoI and NotI sites of 
psiCHECK-2 (Promega, Dübendorf, Switzerland).  PROX1 3’UTR and CDS luciferase 
reporter vectors (Supplementary Table 1) were constructed by PCR amplification from 
YH1551 using the oligonucleotides listed in Supplementary Table 1. PROX1 3’UTR 
amplicons were ligated into the XhoI and NotI sites of psiCHECK-2 and the PROX1-CDS 
amplicon into the PmeI and NotI sites of psiCHECK-2.  
 
Luciferase Reporter Assays 
 
 For miR-31 overexpression optimization, 500,000 LECs were co-transfected with 0.7 
µg pMIR-Luci/miR31BS, 0.7 µg pMIR-REPORT β-Galactosidase (β-gal) control and 0.02 
µM, 0.2 µM, 1 µM, 2 µM or 4 µM human miR-31 precursor (Pre-miR-31) or Pre-miR-Neg 
negative control molecules (Applied Biosystems).  Luciferase and β-gal activities were 
monitored 48 hours after transfection using the Dual-Light Luciferase and β-gal Reporter 
Gene Assay System (Applied Biosystems). β-gal RLUs (Relative Light Units) were used to 
normalize luciferase RLUs. 
 For the PROX1 3’UTR tethering and PROX1 3’UTR miR-31 binding site 
mutagenesis assays, 500,000 LEC or HUVECs were co-transfected in triplicate with 4 µM of 
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miR-31 precursor or inhibitor(6)  or the corresponding negative controls and 0.7 µg of the 
psiCHECK-2 constructs containing the miR-31 binding site (miR31BS), the PROX1 3’UTR 
fragments (PROX1 FL-F6), the PROX1 coding sequence (PROX1 CDS), or the PROX1 
3’UTR miR-31 binding site mutants (PROX1 FLmut or PROX1 F6mut) (Supplementary 
Table 1).  Firefly and Renilla luciferase activities were monitored 48 hours after transfection 
using the Dual-Luciferase Reporter Assay System (Promega). PROX1 3’UTR/CDS-Renilla 
luciferase RLUs were normalized to firefly luciferase RLUs. Both the Dual-light and Dual-
luciferase assays were performed in triplicate with 20 µL of cell lysate. 
 
Xenopus microinjection and whole-mount in situ hybridization 
 Xenopus studies were conducted under protocols approved by the Veterinary Office 
of the Canton of Zürich, Switzerland. Xenopus laevis eggs were obtained by hormone-
induced laying, fertilized in vitro and prepared for microinjection as previously described(21). 
2-cell stage embryos were unilaterally microinjected with Pre-miR-31 or Pre-miR-Neg 
molecules (10-100 ng/blastomere) and 0.2 ng β-galactosidase RNA (lineage tracer). The 
antisense VEGFC MO (5’-GTAACGCTCCCTCCAGCAAGTACAT-3’) was purchased from 
Gene Tools (Philomath, OR) and 5 to 10 ng were unilaterally injected into two-cell-stage 
embryos. When uninjected embryos reached the embryonic stage indicated, the injected 
embryos were fixed and processed for in situ hybridization. Whole-mount in situ 
hybridization, β-galactosidase staining, and bleaching of Xenopus embryos were carried out 
as previously described(29). Digoxigenin-labeled probes were transcribed from linearized 
plasmids encoding Xenopus pecam1(29), prox1 (GenBank Acc. No. BU903551), and vegfr3 
(Kalin et al. 2009). Images were acquired digitally using AxioVision 4.5 (Zeiss) software and 
an AxioCam color camera (Zeiss) mounted on a Zeiss Stereo Lumar V12 stereoscopic 
microscope. 
Zebrafish microinjection 
 Transgenic TG(fli1a:gfp)y1(37) and plcg1 t26480 zebrafish lines were maintained in the 
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Hubrecht Institute. Zebrafish experiments were approved by the Animal Experimentation 
Committee (DEC) of the Royal Netherlands Academy of Arts and Sciences. The plcg1t26480 
allele encodes a W1024Stop mutation in the plcg1 gene (GenBank accession number 
AY163168).  
 Morpholino oligomers were ordered from Gene Tools (Philomath, OR). One cell stage 
TG(fli1a:gfp)y1:plcg1t26480 mutant embryos were injected with 40 ng/embryo of MOs targeting 
dre-miR-31 (5’-TTAACAGCTATGCCAACATCTTGCC-3’), or 25 ng/embryo of an 
unrelated control MO (5’-GCATTGACTCTGTAAAACAGACAAT-3’). For miR-31 
overexpression, TG(fli1a:gfp)y1:plcg1t26480 mutant embryos were injected with 1 nl of 25 µM 
human Pre-miR-31 precursor or Pre-miR-Neg control molecules (Applied Biosystems). 
Venous sprouts were quantified at 48 hpf and statistical significance analyzed using the 
Student’s t-test. For imaging, embryos were mounted in 0.8% low melting point agarose in a 
dish with a cover slip replacing the bottom. Imaging was performed with a Leica SP2 
confocal microscope (Leica Microsystems) using a 20x objective. 
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Results 
BVEC versus LEC lineage-specific miRNA expression 
 Using a TaqMan-based qRT-PCR profiling platform(5) we defined the in vitro 
expression profiles of 157 human miRNAs in primary LECs and BVECs, as well as two non-
endothelial cell types (HaCaT keratinocytes and dermal fibroblasts (hdFBs)) (Supplementary 
Table 2). Following data normalization, expression profiles for each cell-type were defined by 
setting the Ct value present call cut-off at 34 (Supplementary Table 2). Most of the miRNAs 
analyzed were expressed at comparable levels in both LECs and BVECs (Supplementary 
Figure 1). Nevertheless, based on a two-fold or greater differential expression, 16 candidate 
LEC- and 30 candidate BVEC-signature miRNAs were identified (Table 1). Using a p-value 
cut-off of ≤0.05, 2 LEC-signature miRNAs (miR-95 and miR-326) and 4 BVEC-signature 
miRNAs (miR-137, miR-31, miR-125b and miR-99a) were identified (Table 1). Individual 
TaqMan miRNA assays confirmed the vascular lineage specificity of these miRNAs. miR-95 
and miR-326 were, on average, 46-fold and 7-fold higher in LECs than in BVECs, 
respectively (Figure 1A). Conversely, miR-137 expression was 124-fold higher in BVECs 
than in LECs, miR-31 was 48-fold higher in BVECs, and miR-125b and miR99a were 3-fold 
more abundant in BVECs (Figure 1B). 
 
LEC- and BVEC-signature miRNA expression patterns are maintained in vivo  
 We next isolated BVECs and LECs from the colons of 8 adult mice by FACS sorting, 
using the leukocyte marker CD45, the pan-endothelial marker CD31 and the LEC marker 
podoplanin to differentiate between leukocytes (CD45+CD31–podoplanin– and 
CD45+CD31+podoplanin–), BVECs (CD45–CD31+podoplanin–) and LECs (CD45–
CD31+podoplanin+)(18). We obtained 1500 to 25000 LECs and 2500 to 55000 BVECs, from 
which total RNA was extracted and used for ex vivo qRT-PCR miRNA profiling. Based on a 
1.5-fold or greater differential expression, miR-31 was indeed more strongly expressed by 
BVECs than LECs in 6 of 8 mice analyzed (Figure 2A). The degrees of miR-31 differential 
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expression between mouse BVECs and LECs in vivo were less pronounced than those 
observed between in vitro cultured human endothelial cells.  Nevertheless, statistical analysis 
of these in vivo data confirmed that the differences in miR-31 expression between mouse 
BVECs and LECs were statistically significant in 6 out of the 8 mice studied (Figure 2A). 
The LEC-signature expression pattern of miR-326 and the BVEC-signature classifications of 
miR-125b and miR-99a were also confirmed, while no major changes were found for miR-
137 (Supplementary Figure 2). miR-95 is not present in mice.  
 Low magnification (2.5x) microscopic analysis of adult mouse colon tissue sections 
probed for miR-31 expression by ISH revealed strong miR-31 staining throughout the adult 
mouse colon (Figure 2B and D). Importantly, immunofluorescence staining of serial sections 
for the panvascular marker CD31 and the lymphatic marker LYVE-1 revealed that miR-31 
preferentially co-localized with blood vessels (CD31+LYVE1-) present in the submucosa and 
mesenteric attachments of the colon, as well as the lamina propria (Figure 2B and D, arrows 
and arrowheads). In contrast, miR-31 expression was weak or absent in lymphatic vessels 
(Figure 2B and D, asterisks). Independent CD31 and LYVE1 immunofluorescence staining 
and negative control (sense-miR-159) ISH of serial sections of adult colon tissues (Figure 2 H 
and I), coupled with high magnification (20x) image analysis of the miR-31 ISH and the 
CD31/LYVE1 immunofluorescently labeled serial sections, demonstrated no preferential 
staining of either the blood and lymphatic vessels in the sense-miR-159 probed sections 
(Figure 2H and I).  Both vessel types developed equivalent, background level signals 
following ISH processing. By contrast, miR-31 molecules were preferentially associated with 
colonic blood vessels (CD31+LYVE1-; arrows), while the lymphatic vessels 
(CD31+LYVE1+) developed no miR-31 signals (asterisks) (Figure 2F and G). Taken 
together, these in vitro and in vivo data demonstrate that miR-31 transcripts are rare or absent 
in LECs, but enriched in BVEC. 
miR-31 gene synteny is evolutionarily conserved 
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 miR-31 is encoded within intron 1 of an uncharacterized gene – LOC554202 
(GeneID: 554202). This led us to question if miR-31 lineage-specificity results from 
preferential expression of LOC554202 in BVECs. Indeed, TaqMan-based qRT-PCR analysis 
demonstrated that LOC554202 transcripts were 54-fold more abundant in BVECs compared 
to LECs (∆∆Ct=5.78; Supplementary Figure 3A), which is comparable to the degree of 
differential expression defined for miR-31 in BVECs compared to LECs (∆∆Ct=5.58). 
Interestingly, further genome and proteome bioinformatic analyses revealed that the gene is 
not conserved in vertebrates and the putative gene product has no homology to proteins of 
known function. Thus, LOC554202 might primarily function as a conduit for miR-31 post-
transcriptional regulatory activities in BVECs. Sequence alignments of human LOC554202 
with 23 eutherian mammals EPO (Enredo Pecan Ortheus) using Ensembl alignment tools 
(http://www.ensembl.org/index.html) revealed conserved synteny for miR-31 with 6 of the 
species queried. Moreover, 13 of the euterian mammals queried are predicted to encode novel 
miRNA genes at positions aligned with LOC554202 (data not shown). Further alignment 
analysis of these 20 miRNA genes demonstrated that these 13 novel miRNA genes are, in 
fact, miR-31 orthologs (Supplementary Figure 3B). The highly conserved synteny suggests 
that the genomic, transcriptional, and epigenetic factors regulating miR-31 expression have 
remained conserved during mammalian evolution. 
 
Identification of LEC- and BVEC-signature genes regulated by miR-31 
 The strong differential expression of miR-31 in vitro and in vivo prompted us to 
further characterize this BVEC-signature miRNA by defining the transcriptome profile 
changes in LECs after miR-31 overexpression. Using a luciferase reporter construct 
containing a miR-31 binding site (pMIR-Luci/miR31BS) and qRT-PCR, we found that high 
levels of miR-31 gain-of-function could be achieved when LECs were transfected with 2 µM 
Pre-miR-31 precursor(30) (Supplementary Figure 4). Using ≥1.5-fold differential expression 
and ≤0.05 p-value thresholds, gene microarray analyses of 2 µM Pre-miR-31 or Pre-miR-Neg 
transfected LECs identified 548 miR-31-repressed and 335 miR-31-induced genes 
 at Universitaet Zuerich on M
ay 19, 2010 
m
cb.asm
.org
D
ow
nloaded from
 
 17 
(Supplementary Tables 3 and 4). Comparing the miR-31 targets predicted by TargetScan(17, 
39), miRanda(27), miRBase(16) and PicTar(31), 7.2% of the miR-31-repressed genes were 
predicted targets of miR-31.  
 In silico biological process analysis, using the Panther Classification System(61, 62), 
was used to assess whether the observed miR-31-mediated reprogramming of LECs 
specifically affected lymphatic, blood vascular and/or endothelial biological functions. 
Intriguingly, genes involved in cell communication, signal transduction, cell adhesion, 
apoptosis and numerous signaling pathways were overrepresented among the miR-31-
repressed genes compared to the expected number of genes (Supplementary Table 5).  While 
these biological processes are common to both endothelial cell types, this enrichment 
suggests a dramatic re-organization of the LECs cell surface characteristics, as well as cell 
signaling network activity, following miR-31 overexpression.  The specific effects miR-31 
overexpression had on genes involved in vascular lineage-specific differentiation were then 
identified by comparing the miR-31-regulated genes to the LEC- (344 genes) and BVEC-
signature genes (479 genes) previously identified in vitro (23, 32, 48 and Shin et al., 
submitted for review). Interestingly, twice as many transcripts encoding LEC-signature 
molecules (9.6%) than BVEC-signature molecules (4.8%) were reduced following miR-31 
overexpression (Figure 3A and B, and Supplementary Table 3). Also, approximately 4 times 
more BVEC-signature genes (4.6%) were induced/stabilized following miR-31 
overexpression compared to LEC-signature genes (1.1%) (Figure 3A and B, and 
Supplementary Table 4). Corroborating the microarray data, qRT-PCR experiments 
confirmed that four LEC-signature genes (EDNRB, PROX1, PPP1R9A, HOXD10) and two 
BVEC-signature genes (ICAM1, SELE) tested were significantly less abundant in the Pre-
miR-31 samples compared to Pre-miR-Neg control (Figure 3C and D). Furthermore, we also 
validated the up-regulation of the miR-31-induced BVEC-signature genes MMP1 and RGS4 
(Figure 3E). 
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miR-31 inhibits PROX1 protein translation 
 Amongst the miR-31-repressed target genes was PROX1, an essential lymphatic-
specific transcription factor(1, 7). qRT-PCR analysis confirmed that transfection of LECs 
with 4 µM Pre-miR-31 resulted in a ≥60% reduction in PROX1 transcripts (Figure 4A), which 
was further verified by Northern blotting (Supplementary Figure 5). Importantly, 
immunoblotting revealed a consistent decrease in PROX1 protein levels by <40% following 
miR-31 overexpression (Figure 4B and C). Similar, but less consistent, results were observed 
after transfection with 2 µM Pre-miR-31 (Supplementary Figure 6). Conversely, loss-of miR-
31 function in BVECs, via transfection of HUVECs with miR-31 inhibitor molecules (Anti-
miR-31), resulted in a 1.7−3.1-fold increase in PROX1 mRNA levels (Figure 4D). PROX1 
protein remained undetectable in these samples (data not shown).  
 
PROX1 is a direct target of miR-31 post-transcriptional regulation 
 PROX1 was not predicted to be a target of miR-31 by TargetScan(17, 39), 
miRanda(27), miRBase(16) or PicTar(31), but human cells express two isoforms of PROX1 
mRNA: A 7.9Kb isoform, which contains a 5.4Kb 3’UTR; and a 3.1Kb isoform that has a 
much shorter 602bp 3’UTR(57). Only the short 3’UTR has thus far been used for miRNA 
binding site predictions. In agreement with previous studies(25, 26, 49), our LECs expressed 
the longer, 7.9Kb isoform of PROX1 (Supplementary Figure 5). Therefore, standard nucleic 
acid alignment techniques (SIM alignment tools) and independent Tragetscan 5.0 analyses 
were used to identify potential miR-31 binding sites in the 5.4Kb 3’UTR. SIM alignment 
identified 5 potential miR-31 recognition sites and the Targetscan search identified one of 
these sites, nucleotides (n.t.) 949-971, as a 7mer-m8 binding site (Figure 5A and 
Supplementary Table 6).  
 To test the functional relevance of these candidate miR-31 binding sites luciferase 
reporter genes containing a full-length PROX1 3’UTR (PROX1 FL), 6 PROX1 3’UTR 
fragment (PROX1 F1-6) (Figure 5A), or a PROX1 coding sequence (CDS) were constructed. 
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The activities of these chimeras were monitored following miR-31 gain-of-function in LECs 
(Figure 5B) and loss-of-function in HUVECs (Figure 5C). Confirming Pre-miR-31 
overexpression and Anti-miR-31 knockdown activity, miR-31 binding site (miR-31 BS) 
luciferase reporter gene activity decreased or increased by <40% when co-transfected with 
Pre-miR-31 or Anti-miR-31 molecules, respectively (Figure 5B and C). The luciferase 
activities of PROX1 FL and PROX1 F2 reporter genes, which contain the 7mer-m8 site, 
decreased significantly (>35% and >45%, respectively) following miR-31 overexpression 
(Figure 5B). Conversely, their activities increased >14-fold and 3-fold, respectively, after 
miR-31 inhibition (Figure 5C). While PROX1 3’UTR F1 and F4 reporter gene activities 
increased after miR-31 knockdown, reciprocal responses following overexpression were not 
observed. Together, these findings confirm the direct post-transcriptional regulation of 
PROX1 by miR-31, and suggested that this regulation is mediated via n.t. 949-971 of the 
5.4Kb 3’UTR. 
 To validate this, the seed sequence (n.t. 964-971) and 3’ compensatory site 
interacting nucleotides (n.t. 954-960) the of the PROX1 3'UTR were mutated to match the 
miR-31 sequence in both the PROX1 FL and PROX1 F2 luciferase reporter plasmids, thus 
eliminating the predicted PROX1:miR-31 interaction. While the luciferase activities of the 
wild-type the PROX1 FL and PROX1 F2 constructs decreased or increased after miR-31 
overexpression or knockdown, respectively (Figure 5D), the activities of the mutant full-
length and F2 fragment luciferase reporter genes did not change significantly under either 
condition. Thus, mapping a bona fide, biologically active miR-31 binding site to n.t 949-971 
of the PROX1 3’UTR.  
 
miR-31 overexpression inhibits PROX1 target genes  
 Numerous studies have demonstrated the PROX1 transcriptional activities help 
dictate the molecular characteristics and functional activities of vascular endothelial cells(12, 
26, 44, 48 and Shin et al., manuscript in preparation). Therefore, our characterization of 
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PROX1 as a target of miR-31 post-transcriptional regulation suggested miR-31 repression of 
PROX1 should specifically, albeit indirectly, alter the expression PROX1 target genes. 
Comparing the miR-31-regulated genes identified above with a PROX1 loss-of-function 
dataset generated following lentiviral inhibition of PROX1 in LECs (Shin et al, manuscript in 
preparation) revealed that approximatedly 20% of the miR-31-repressed and -induced genes 
were similarly repressed or induced, respectively, following Prox1 knockdown 
(Supplementary Table 3 and 4). Intriguingly, <50% of the miR-31-repressed LEC-signature 
genes (Supplementary Table 3) and 36% of the miR-31-induced BVEC-signature genes 
(Supplementary Table 4) were similarly differentially expressed following PROX1 depletion 
from LECs.  
 
miR-31 regulates vascular development in vivo 
 During embryogenesis PROX1 is expressed in a subpopulation of cardinal vein 
endothelial cells that give rise to the mammalian lymphatic vascular system(1, 7). The 
BVEC-specific expression of miR-31, together with its ability post-transcriptionally repress 
numerous BVEC- and LEC-signature genes (Supplementary Tables 3 and 4), including 
Prox1, suggested that this miRNA might play a role in vascular development. As many of the 
BVEC- and LEC-signature genes targeted by miR-31 also play a major roles in Xenopus 
vascular development(9, 20, 45), we reasoned that ectopic expression of miR-31 in early 
Xenopus embryos might interfere with lymphatic vascular development. To investigate this, 
2-cell stage Xenopus embryos were unilaterally microinjected with human Pre-miR-31 or Pre-
miR-Neg molecules. Lymphatic and blood vascular system development were then monitored 
in stage 39 embryos using whole-mount in situ hybridization (ISH) for specific lymphatic and 
blood vascular marker genes(28, 29, 45).  
 No gross developmental defects or externally visible phenotypes were observed 
following Pre-miR-Neg or Pre-miR-31 microinjection into Xenopus embryos (Figure 6). 
Moreover, prox1 and vegfr3 marker gene analysis demonstrated that lymphatic vascular 
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development progressed normally in 95% and 79% of the Pre-miR-Neg control embryos, 
respectively (Table 2). The embryos had well-defined and clearly visible lymph hearts, lymph 
vessels, and punctate patches of LECs in their tails (Figure 6A and B). In contrast, a dose-
dependent increase in lymphatic vascular defects was observed in Pre-miR-31 injected 
embryos. Specifically, vefgr3 ISH demonstrated that the percentage of embryos with 
lymphatic vascular defects as monitored by the loss of vegfr3-positive lymphatics sprouting 
from the lymph hearts progressively increased from 6.1 to 76.2% as the amounts of Pre-miR-
31 molecules increased from 1 ng to 50 ng (Table 2). Generally, lymph hearts were present in 
these embryos but appeared smaller and less well-defined compared to control embryos 
(Figure 6A and B) or the uninjected side of the Pre-miR-31 embryos (data not shown). 
Moreover, lymphangiogenesis, scored by the presence of vegfr3-expressing lymphatic vessels 
sprouting from the lymph heart, was either strongly reduced or absent in the presence of 
excess miR-31 (Figure 6A and B). These phenotypes were similar to those observed 
following morpholino inhibition of vegfc, where lymphangiogenesis was disrupted in the 
lymph heart region of 67-100% (N=3, total embryos analyzed: 71) of the injected Xenopus 
embryos (Supplementary Figure 7).  
 Pecam1 expression was used to monitor blood vascular system development in Pre-
miR-Neg and Pre-miR-31 microinjected Xenopus embryos. In control embryos, all of the 
major blood vascular structures such as the posterior cardinal veins and the dorsal aorta were 
clearly visible, and angiogenic sprouting of intersomitic veins occurred normally in 73% of 
the Pre-miR-Neg injected embryos (Figure 6C and Table 2). By comparison, the percentage 
of embryos displaying unilateral intersomitic vein growth and/or guidance defects 
progressively increased from 0% to 76% with increasing amounts of Pre-miR-31 injected 
(Figure 6C and Table II).  
 Gain-of-function phenotypes can occasionally be attributed to the off-target effects 
associated with non-physiological expression levels of an siRNA or miRNA(41, 51). We, 
therefore, sought to confirm the Xenopus miR-31 overexpression phenotypes in zebrafish, 
another highly relevant vertebrate model organism for studying blood and lymphatic vascular 
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development(40). To facilitate the quantification of venous sprouting from the posterior 
cardinal vein (PCV)(24, 33, 67), we used phospholipase C gamma-1 (plcg1) mutant embryos 
in the TG(fli1a:gfp)y1 background(36) (TG(fli1a:gfp)y1:plcg1t26480), in which only the venous 
sprouts contributing to both the blood and lymphatic vasculature are visible. Venous 
sprouting was quantified 48 hpf following injection of 170 pg or 340 pg of either human Pre-
miR-31 precursor or Pre-miR-Neg control molecules (Table 3 and Figure 7A). In agreement 
with our Xenopus studies, a significant dose-dependent reduction in venous sprouting was 
observed in Pre-miR-31 injected embryos compared to embryos injected with 340 pg Pre-
miR-Neg molecules or to uninjected controls (Table 3 and Figure 7). The increase in venous 
sprouting observed in Pre-miR-Neg injected embryos (Figure 7B and C) appears to be a stress 
response, which we have also observed in a number of unrelated control injections (data not 
shown). Conversely and importantly, miR-31 overexpression led to a highly significant 
reduction in venous sprouting and no other developmental defects were observed in these 
embryos (Table 3 and Figure 7A and D). 
 Venous sprouting and lymphangiogenesis were also monitored in zebrafish embryos 
following injection of increasing concentrations of morpholino oligonucleotides (MO) 
targeting both mature and precursor dre-miR-31. Significant vascular phenotypes could not be 
specifically attributed to loss-of miR-31 activity in these embryos (data not shown). Taken 
together, our miR-31 gain-of-function studies in Xenopus and zebrafish embryos indicate that 
appropriate expression levels of miR-31 during vertebrate embryogenesis are required for 
normal lymphatic and blood vascular development. 
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Discussion 
 
 In the study presented here we first defined the in vitro expression profiles of 157 
human miRNAs in primary human LECs and BVECs using a TaqMan-based qRT-PCR 
profiling platform, whose increased sensitivity facilitated the detection of at least twice as 
many miRNAs in HUVECs as previously reported(19, 34, 50, 58, 66). We also found that one 
of the most highly expressed HUVEC miRNAs, miR-126(19, 34, 50, 58, 66), was >600 times 
more abundant in both endothelial cell types than in either keratinocytes or fibroblasts. 
Comparative analysis identified 4 BVEC- and 2 LEC-signature miRNAs. Of the 4 BVEC-
signature miRNAs, 3 were previously reported as highly expressed in HUVECs(19, 34, 50, 
58, 66), and a very recent study has demonstrated that TNF treatment augments miR-31 
expression in HUVECs(60: 2010). Moreover, our miRNA profiling study has further 
classified the widely-expressed(38), metastasis-associated(63, 64)  miRNA miR-31 as a 
BVEC-signature miRNA.  Finally, in agreement with their LEC-specific expression, neither 
miR-95 nor miR-326 were detected in the previous studies.  
 Importantly, further analysis of miR-31, miR-326, miR-125b and miR-99a in adult 
mouse tissues confirmed that their vascular lineage-specific expression patterns were 
maintained in vivo.  The degrees of lineage-specific expression differences in vivo were, 
however, usually less pronounced and more variable than those observed in vitro. This is 
likely due to the mixed populations of BVECs and LECs isolated from the multiple vessel 
types present in the colon tissue (capillaries, postcapillary venules, lymphatic capillaries, 
lymphatic collecting vessels etc.), which likely exhibit different gene expression patterns. 
Moreover, their relative contributions to the isolated total RNA might vary, thus contributing 
to larger variability in miRNA expression patterns. In addition, the ex vivo miRNA expression 
profiling studies were technically challenging as the whole process took more than 2 hours 
and only a few thousand endothelial cells could be isolated by high-speed cell sorting. 
Consequently, the smaller amounts of isolated total RNA, reduced RNA quality and possible 
gene expression changes incurred during the 2-hour isolation procedures likely contributed to 
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the observed differences of in vivo and in vitro miR-31 expression, as well as to the observed 
inter-individual variability of miR-31 expression. Surprisingly, we were unable to confirm the 
differential expression patterns of miR-137 in vivo. This is likely because miR-137 expression 
levels were very low in the adult tissues analyzed here as indicated by the late qRT-PCR 
detection (Ct > 35) and high standard deviations between technical replicates. ISH analysis of 
chicken embryos revealed that miR-137 is expressed in blood vessels and cardinal veins at 
stage 25 of embryonic development(8), demonstrating that miR-137 expression is associated 
with the developing blood vasculature. 
 The identification of vascular lineage-specific miRNAs suggested that they might 
regulate fundamental and lineage-specific endothelial cell functions and/or differentiation 
processes. Indeed, overexpression of the BVEC-specific miRNA, miR-31, in LECs induced 
the preferential degradation of LEC-signature genes, including the well-characterized 
lymphatic transcription factors PROX1 and FOXC2. As these lymphatic-specific molecules 
act as molecular switches, their preferential suppression suggests that BVEC-specific post-
transcriptional regulatory mechanisms help maintain BVEC phenotypes by suppressing 
lymphatic-specific transcription programs. This concept was supported by our findings that 
ectopic overexpression of miR-31 in LECs preferentially repressed LEC-signature gene and 
induced BVEC-signature gene expression. In this respect, our identification and validation of 
PROX1 as a direct miR-31 target is an intriguing finding as BVEC-specific post-
transcriptional regulation of PROX1 could, at least in part, explain these in vitro miR-31-
mediated reprogamming events on the molecular level. Indeed, previous studies have 
demonstrated that PROX1 overexpression in BVECs induces the expression of lymphatic 
vascular markers and suppresses blood vascular markers(26, 48), whereas PROX1 
knockdown in LECs inhibits LEC-signature gene expression and triggers BVEC-signature 
gene expression (44 and Shin et al., manuscript in preparation). Moreover, the overlaps 
between the miR-31-regulated genes identified here and a PROX1 loss-of-function dataset, 
further indicate that transcriptional reprogramming events observed following miR-31 
overexpression in LECs were, in part, mediated by miR-31 repression of Prox1. Additional 
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experiments are required to determine which of the miR-31-regulated candidate Prox1 target 
genes may also be direct targets of miR-31. 
 While PROX1 was not a predicted target gene of miR-31(16, 17, 27, 31, 39), our 
manual miR-31 site prediction analyses of the 5.4 Kb PROX1 3’UTR and subsequent 
luciferase 3’UTR tethering assays identified a bona fide miR-31 binding site between 
nucleotides 949-971 of the PROX1 3’UTR. Interestingly, similar manual miR-31 prediction 
analyses of the chimpanzee, mouse, rat, chicken, Xenopus and zebrafish PROX1 3’UTRs 
revealed that this site is evolutionarily conserved in vertebrates, and identified additional, 
potentially functional miR-31 binding sites (Supplementary Table 6). Taken together, our 
transcriptome profiling and biochemical studies have revealed a novel, highly conserved 
BVEC-specific post-transcriptional regulatory mechanism that suppresses PROX1 expression 
in the blood vasculature.  
 Our findings also suggested that miR-31 expression in the developing blood vascular 
endothelium could regulate the acquisition of lymphatic-specific characteristics and, thus, 
vascular development in vivo. Multiple miR-31 loss-of-function studies using morpholino 
oligonucleotides were performed in both wild-type and plcg1 mutant zebrafish embryos. 
Statistically significant vascular phenotypes were not observed in zebrafish embryos injected 
with low to moderate (≤10 ng) amounts of MOs (data not shown). This suggests that the 
miR31-mediated regulation of vascular development identified here is redundant. This is not 
surprising, since miRNAs frequently function cooperatively(3, 15, 17), which in turn 
complicates the attribution of specific functions to individual miRNAs(53). In contrast, 
miRNA gain-of-function experiments have proven very informative and have defined 
important biological functions for several miRNAs(42, 43, 53). For example, overexpression 
studies in Xenopus embryos have demonstrated that miR-15 and miR-16 restrict in vivo the 
size of the Spemann’s organizer by targeting the Nodal-type II receptor acrvr2a(42). We, 
therefore, carried out miR-31 overexpression studies in Xenopus and zebrafish embryos to 
determine the effect of miR-31 on cells and tissues that  normally do not express miR-31, 
such as the lymphatic vasculature.  
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 Our gain-of-function experiments clearly demonstrated that miR-31 expression is 
incompatible with normal lymphatic vascular development in Xenopus and, to a lesser extend, 
zebrafish embryos. The analysis in Xenopus embryos suggests that some aspects of lymphatic 
vascular development, such as specification of lymph hearts and LECs in the tail, are 
unaffected by miR-31 overexpression. Lymphangiogenesis and the development of an 
extensive lymphatic vasculature in the embryonic trunk is, however, clearly reduced and/or 
disrupted. Furthermore, we demonstrated that these observed lymphatic defects were 
reminiscent of those observed following MO-mediated inhibition of vegfc. These phenotypic 
similarities indicate that miR-31 overexpression interferes with an early step of lymphatic 
development. The identification of evolutionarily conserved miR-31 binding sites in PROX1 
3’UTRs (Supplementary Table 6) suggests that miR-31 overexpression may directly target 
and interfere with PROX1 transcripts in vivo. Moreover, the abnormal or disrupted 
intersomitic vein sprouting in Xenopus and zebrafish embryos (data not shown) following 
miR-31 overexpression, implies that miR-31 also regulates BVEC responsiveness to the 
environmental stimuli directing blood vascular growth and maturation. Interestingly, several 
genes involved in the Slit/Robo, netrin, and ephrin signaling pathways (Supplementary Table 
3), which provide crucial guidance cues during blood vascular development(1), were 
repressed following miR-31 gain-of-function in vitro. In vivo post-transcriptional regulation 
of any one of these molecules by miR-31 could contribute to the observed blood vascular 
maturation defects. Taken together, our results indicate that appropriate expression of miR-31 
during vertebrate embryogenesis is required for both lymphatic vascular development and 
blood vascular growth and maturation. Interestingly, our in vivo studies also correlate well 
with a recent study demonstrating that miR-31 controls the invasive capacity of breast cancer 
cells(63, 64). Collectively, these studies suggest roles for miR-31 in the regulation of cell 
migratory behavior during embryonic normal development and under pathological conditions 
in the adult body.   
 On the basis of the in vitro studies, we postulate that PROX1 transcripts represent one 
of the key targets of miR-31.  This repression would prevent in appropriate and/or premature 
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transcriptional activation of lymphatic differentiation in the developing blood vasculature. 
While this notion is an attractive model, it is however important to stress that miR-31 targets 
several other LEC-signature genes. It is, therefore, unlikely that post-transcriptional 
repression of PROX1 by miR-31 is solely responsible for the vascular developmental defects 
observed in Xenopus and zebrafish embryos overexpressing miR-31. For example, miR-31-
mediated repression of FOXC2, a transcription factor that is required for specification of the 
lymphatic capillaries versus collecting lymphatic vessels at later stages of embryogenesis(1, 
7), may also contribute to the vascular defects. Another miR-31 candidate target is RAMP2, a 
calcitonin receptor-like receptor associated receptor activity-modifying protein that triggers 
lymphangiogenesis in response to adrenomedullin signaling(13). Finally, other LEC-signature 
molecules subject to miR-31 regulation, whose lymphatic-specific functions have not yet 
been characterized, could also enhance the effects miR-31 has on lymphatic and blood 
vascular development.  
The miRNAs profiled in the present study represent  approximately only 25 % of all 
known human miRNAs. Thus, more comprehensive and global miRNA profiling studies 
along the lines outlined in the present studies may result in the identification of additional 
endothelial lineage-specific miRNAs. In summary, we have defined the first vascular lineage-
specific miRNAs and identified with miR-31 a novel miRNA-mediated regulatory 
mechanism that inhibits LEC phenotype acquisition in vitro and vascular development in 
vivo. From a therapeutic perspective, it remains to be investigated whether the ectopic 
expression of miR-31 might also inhibit malignant tumor-associated (lymph)angiogenesis, 
thus preventing tumor growth and cancer metastasis.  
 at Universitaet Zuerich on M
ay 19, 2010 
m
cb.asm
.org
D
ow
nloaded from
 
 28 
Acknowledgements 
 
 This work was supported by National Institutes of Health grant CA69184, Swiss 
National Science Foundation grant 3100A0-108207, Austrian Science Foundation grant 
S9408-B11, Cancer League Zurich, Commission of the European Communities grant LSHC-
CT-2005-518178 (M.D.); Swiss National Science Foundation grant 3100A0-101964 
(A.W.B.); and EMBO Long-term fellowships ALTF 1104-2007 (D.M.L.P.) and ALTF 52-
2007 (T.K.). 
 
 We thank Dr. Young Kwon Hong for the PROX1 3’UTR plasmid (YH1551), Drs. 
Salvatore Oliviero, Jay W. Shin and Ahmad Salameh for sharing the PROX1 lentivirus 
knockdown microarray dataset, Dr. Patrick Pedrioli for bioinformatic assistance and critical 
reading of the manuscript, and Jana Zielinski, Cornelius Fischer and Jeannette Scholl for 
expert technical assistance. We would also like to thank the Tübingen 2000 screen consortium 
for identifying the plcg1t26480 allele.  
 
 D.M.L.P. and T.K. designed and performed research experiments, analyzed the data 
and wrote the manuscript. V.D., G.J., G.V., D.H., and R.E.K., designed and performed 
research experiments, and analyzed the data. D.M., J.W.S., S.L., and P.C. performed research 
experiments and analyzed the data. M.D., A.W.B., and S.S-M. designed research 
experiments, analyzed the data, and wrote the manuscript. 
 at Universitaet Zuerich on M
ay 19, 2010 
m
cb.asm
.org
D
ow
nloaded from
 
 29 
References 
1. Adams, R. H., and K. Alitalo. 2007. Molecular regulation of angiogenesis and 
lymphangiogenesis. Nat Rev Mol Cell Biol 8:464-78. 
2. Amatschek, S., E. Kriehuber, W. Bauer, B. Reininger, P. Meraner, A. Wolpl, N. 
Schweifer, C. Haslinger, G. Stingl, and D. Maurer. 2007. Blood and lymphatic 
endothelial cell-specific differentiation programs are stringently controlled by the 
tissue environment. Blood 109:4777-85. 
3. Antonov, A. V., S. Dietmann, P. Wong, D. Lutter, and H. W. Mewes. 2009. 
GeneSet2miRNA: finding the signature of cooperative miRNA activities in the gene 
lists. Nucleic Acids Res 37:W323-8. 
4. Boukamp, P., R. T. Petrussevska, D. Breitkreutz, J. Hornung, A. Markham, and 
N. E. Fusenig. 1988. Normal keratinization in a spontaneously immortalized 
aneuploid human keratinocyte cell line. J Cell Biol 106:761-71. 
5. Chen, C., D. A. Ridzon, A. J. Broomer, Z. Zhou, D. H. Lee, J. T. Nguyen, M. 
Barbisin, N. L. Xu, V. R. Mahuvakar, M. R. Andersen, K. Q. Lao, K. J. Livak, 
and K. J. Guegler. 2005. Real-time quantification of microRNAs by stem-loop RT-
PCR. Nucleic Acids Res 33:e179. 
6. Cheng, A. M., M. W. Byrom, J. Shelton, and L. P. Ford. 2005. Antisense 
inhibition of human miRNAs and indications for an involvement of miRNA in cell 
growth and apoptosis. Nucleic Acids Res 33:1290-7. 
7. Cueni, L. N., and M. Detmar. 2006. New insights into the molecular control of the 
lymphatic vascular system and its role in disease. J Invest Dermatol 126:2167-77. 
8. Darnell, D. K., S. Kaur, S. Stanislaw, S. Davey, J. H. Konieczka, T. A. 
Yatskievych, and P. B. Antin. 2007. GEISHA: an in situ hybridization gene 
expression resource for the chicken embryo. Cytogenet Genome Res 117:30-5. 
9. De Val, S., N. C. Chi, S. M. Meadows, S. Minovitsky, J. P. Anderson, I. S. 
Harris, M. L. Ehlers, P. Agarwal, A. Visel, S. M. Xu, L. A. Pennacchio, I. 
Dubchak, P. A. Krieg, D. Y. Stainier, and B. L. Black. 2008. Combinatorial 
regulation of endothelial gene expression by ets and forkhead transcription factors. 
Cell 135:1053-64. 
10. Filipowicz, W., S. N. Bhattacharyya, and N. Sonenberg. 2008. Mechanisms of 
post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev 
Genet 9:102-14. 
11. Fish, J. E., and D. Srivastava. 2009. MicroRNAs: opening a new vein in 
angiogenesis research. Sci Signal 2:pe1. 
12. Francois, M., A. Caprini, B. Hosking, F. Orsenigo, D. Wilhelm, C. Browne, K. 
Paavonen, T. Karnezis, R. Shayan, M. Downes, T. Davidson, D. Tutt, K. S. 
Cheah, S. A. Stacker, G. E. Muscat, M. G. Achen, E. Dejana, and P. Koopman. 
2008. Sox18 induces development of the lymphatic vasculature in mice. Nature. 
13. Fritz-Six, K. L., W. P. Dunworth, M. Li, and K. M. Caron. 2008. Adrenomedullin 
signaling is necessary for murine lymphatic vascular development. J Clin Invest 
118:40-50. 
14. Gentleman, R. C., V. J. Carey, D. M. Bates, B. Bolstad, M. Dettling, S. Dudoit, B. 
Ellis, L. Gautier, Y. Ge, J. Gentry, K. Hornik, T. Hothorn, W. Huber, S. Iacus, 
R. Irizarry, F. Leisch, C. Li, M. Maechler, A. J. Rossini, G. Sawitzki, C. Smith, 
G. Smyth, L. Tierney, J. Y. Yang, and J. Zhang. 2004. Bioconductor: open 
software development for computational biology and bioinformatics. Genome Biol 
5:R80. 
15. Georges, S. A., M. C. Biery, S. Y. Kim, J. M. Schelter, J. Guo, A. N. Chang, A. L. 
Jackson, M. O. Carleton, P. S. Linsley, M. A. Cleary, and B. N. Chau. 2008. 
Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-
192 and miR-215. Cancer Res 68:10105-12. 
 at Universitaet Zuerich on M
ay 19, 2010 
m
cb.asm
.org
D
ow
nloaded from
 
 30 
16. Griffiths-Jones, S., H. K. Saini, S. van Dongen, and A. J. Enright. 2008. 
miRBase: tools for microRNA genomics. Nucleic Acids Res 36:D154-8. 
17. Grimson, A., K. K. Farh, W. K. Johnston, P. Garrett-Engele, L. P. Lim, and D. 
P. Bartel. 2007. MicroRNA targeting specificity in mammals: determinants beyond 
seed pairing. Mol Cell 27:91-105. 
18. Halin, C., N. E. Tobler, B. Vigl, L. F. Brown, and M. Detmar. 2007. VEGF-A 
produced by chronically inflamed tissue induces lymphangiogenesis in draining 
lymph nodes. Blood 110:3158-67. 
19. Harris, T. A., M. Yamakuchi, M. Ferlito, J. T. Mendell, and C. J. Lowenstein. 
2008. MicroRNA-126 regulates endothelial expression of vascular cell adhesion 
molecule 1. Proc Natl Acad Sci U S A 105:1516-21. 
20. Helbling, P. M., D. M. Saulnier, and A. W. Brandli. 2000. The receptor tyrosine 
kinase EphB4 and ephrin-B ligands restrict angiogenic growth of embryonic veins in 
Xenopus laevis. Development 127:269-78. 
21. Helbling, P. M., C. T. Tran, and A. W. Brandli. 1998. Requirement for EphA 
receptor signaling in the segregation of Xenopus third and fourth arch neural crest 
cells. Mech Dev 78:63-79. 
22. Hirakawa, S., L. F. Brown, S. Kodama, K. Paavonen, K. Alitalo, and M. Detmar. 
2007. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor 
metastasis to distant sites. Blood 109:1010-7. 
23. Hirakawa, S., Y. K. Hong, N. Harvey, V. Schacht, K. Matsuda, T. Libermann, 
and M. Detmar. 2003. Identification of vascular lineage-specific genes by 
transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. 
Am J Pathol 162:575-86. 
24. Hogan, B. M., F. L. Bos, J. Bussmann, M. Witte, N. C. Chi, H. J. Duckers, and S. 
Schulte-Merker. 2009. Ccbe1 is required for embryonic lymphangiogenesis and 
venous sprouting. Nat Genet 41:396-8. 
25. Hong, Y. K., K. Foreman, J. W. Shin, S. Hirakawa, C. L. Curry, D. R. Sage, T. 
Libermann, B. J. Dezube, J. D. Fingeroth, and M. Detmar. 2004. Lymphatic 
reprogramming of blood vascular endothelium by Kaposi sarcoma-associated 
herpesvirus. Nat Genet 36:683-5. 
26. Hong, Y. K., N. Harvey, Y. H. Noh, V. Schacht, S. Hirakawa, M. Detmar, and G. 
Oliver. 2002. Prox1 is a master control gene in the program specifying lymphatic 
endothelial cell fate. Dev Dyn 225:351-7. 
27. John, B., A. J. Enright, A. Aravin, T. Tuschl, C. Sander, and D. S. Marks. 2004. 
Human MicroRNA targets. PLoS Biol 2:e363. 
28. Kalin, R. E., N. E. Banziger-Tobler, M. Detmar, and A. W. Brandli. 2009. An in 
vivo chemical library screen in Xenopus tadpoles reveals novel pathways involved in 
angiogenesis and lymphangiogenesis. Blood. 
29. Kalin, R. E., M. P. Kretz, A. M. Meyer, A. Kispert, F. L. Heppner, and A. W. 
Brandli. 2007. Paracrine and autocrine mechanisms of apelin signaling govern 
embryonic and tumor angiogenesis. Dev Biol 305:599-614. 
30. Kiriakidou, M., P. T. Nelson, A. Kouranov, P. Fitziev, C. Bouyioukos, Z. 
Mourelatos, and A. Hatzigeorgiou. 2004. A combined computational-experimental 
approach predicts human microRNA targets. Genes Dev 18:1165-78. 
31. Krek, A., D. Grun, M. N. Poy, R. Wolf, L. Rosenberg, E. J. Epstein, P. 
MacMenamin, I. da Piedade, K. C. Gunsalus, M. Stoffel, and N. Rajewsky. 2005. 
Combinatorial microRNA target predictions. Nat Genet 37:495-500. 
32. Kriehuber, E., S. Breiteneder-Geleff, M. Groeger, A. Soleiman, S. F. 
Schoppmann, G. Stingl, D. Kerjaschki, and D. Maurer. 2001. Isolation and 
characterization of dermal lymphatic and blood endothelial cells reveal stable and 
functionally specialized cell lineages. J Exp Med 194:797-808. 
33. Kuchler, A. M., E. Gjini, J. Peterson-Maduro, B. Cancilla, H. Wolburg, and S. 
Schulte-Merker. 2006. Development of the zebrafish lymphatic system requires 
VEGFC signaling. Curr Biol 16:1244-8. 
 at Universitaet Zuerich on M
ay 19, 2010 
m
cb.asm
.org
D
ow
nloaded from
 
 31 
34. Kuehbacher, A., C. Urbich, A. M. Zeiher, and S. Dimmeler. 2007. Role of Dicer 
and Drosha for endothelial microRNA expression and angiogenesis. Circ Res 101:59-
68. 
35. Kunstfeld, R., S. Hirakawa, Y. K. Hong, V. Schacht, B. Lange-Asschenfeldt, P. 
Velasco, C. Lin, E. Fiebiger, X. Wei, Y. Wu, D. Hicklin, P. Bohlen, and M. 
Detmar. 2004. Induction of cutaneous delayed-type hypersensitivity reactions in 
VEGF-A transgenic mice results in chronic skin inflammation associated with 
persistent lymphatic hyperplasia. Blood 104:1048-57. 
36. Lawson, N. D., J. W. Mugford, B. A. Diamond, and B. M. Weinstein. 2003. 
phospholipase C gamma-1 is required downstream of vascular endothelial growth 
factor during arterial development. Genes Dev 17:1346-51. 
37. Lawson, N. D., and B. M. Weinstein. 2002. In vivo imaging of embryonic vascular 
development using transgenic zebrafish. Dev Biol 248:307-18. 
38. Lee, E. J., M. Baek, Y. Gusev, D. J. Brackett, G. J. Nuovo, and T. D. Schmittgen. 
2008. Systematic evaluation of microRNA processing patterns in tissues, cell lines, 
and tumors. RNA 14:35-42. 
39. Lewis, B. P., C. B. Burge, and D. P. Bartel. 2005. Conserved seed pairing, often 
flanked by adenosines, indicates that thousands of human genes are microRNA 
targets. Cell 120:15-20. 
40. Makinen, T., C. Norrmen, and T. V. Petrova. 2007. Molecular mechanisms of 
lymphatic vascular development. Cell Mol Life Sci 64:1915-29. 
41. Marquez, R. T., and A. P. McCaffrey. 2008. Advances in microRNAs: implications 
for gene therapists. Hum Gene Ther 19:27-38. 
42. Martello, G., L. Zacchigna, M. Inui, M. Montagner, M. Adorno, A. Mamidi, L. 
Morsut, S. Soligo, U. Tran, S. Dupont, M. Cordenonsi, O. Wessely, and S. 
Piccolo. 2007. MicroRNA control of Nodal signalling. Nature 449:183-8. 
43. Mayoral, R. J., M. E. Pipkin, M. Pachkov, E. van Nimwegen, A. Rao, and S. 
Monticelli. 2009. MicroRNA-221-222 regulate the cell cycle in mast cells. J 
Immunol 182:433-45. 
44. Mishima, K., T. Watabe, A. Saito, Y. Yoshimatsu, N. Imaizumi, S. Masui, M. 
Hirashima, T. Morisada, Y. Oike, M. Araie, H. Niwa, H. Kubo, T. Suda, and K. 
Miyazono. 2007. Prox1 induces lymphatic endothelial differentiation via integrin 
alpha9 and other signaling cascades. Mol Biol Cell 18:1421-9. 
45. Ny, A., M. Koch, M. Schneider, E. Neven, R. T. Tong, S. Maity, C. Fischer, S. 
Plaisance, D. Lambrechts, C. Heligon, S. Terclavers, M. Ciesiolka, R. Kalin, W. 
Y. Man, I. Senn, S. Wyns, F. Lupu, A. Brandli, K. Vleminckx, D. Collen, M. 
Dewerchin, E. M. Conway, L. Moons, R. K. Jain, and P. Carmeliet. 2005. A 
genetic Xenopus laevis tadpole model to study lymphangiogenesis. Nat Med 11:998-
1004. 
46. Osada, H., and T. Takahashi. 2007. MicroRNAs in biological processes and 
carcinogenesis. Carcinogenesis 28:2-12. 
47. Pena, J. T., C. Sohn-Lee, S. H. Rouhanifard, J. Ludwig, M. Hafner, A. 
Mihailovic, C. Lim, D. Holoch, P. Berninger, M. Zavolan, and T. Tuschl. 2009. 
miRNA in situ hybridization in formaldehyde and EDC-fixed tissues. Nat Methods 
6:139-41. 
48. Petrova, T. V., T. Makinen, T. P. Makela, J. Saarela, I. Virtanen, R. E. Ferrell, 
D. N. Finegold, D. Kerjaschki, S. Yla-Herttuala, and K. Alitalo. 2002. Lymphatic 
endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox 
transcription factor. Embo J 21:4593-9. 
49. Petrova, T. V., A. Nykanen, C. Norrmen, K. I. Ivanov, L. C. Andersson, C. 
Haglund, P. Puolakkainen, F. Wempe, H. von Melchner, G. Gradwohl, S. 
Vanharanta, L. A. Aaltonen, J. Saharinen, M. Gentile, A. Clarke, J. Taipale, G. 
Oliver, and K. Alitalo. 2008. Transcription factor PROX1 induces colon cancer 
progression by promoting the transition from benign to highly dysplastic phenotype. 
Cancer Cell 13:407-19. 
 at Universitaet Zuerich on M
ay 19, 2010 
m
cb.asm
.org
D
ow
nloaded from
 
 32 
50. Poliseno, L., A. Tuccoli, L. Mariani, M. Evangelista, L. Citti, K. Woods, A. 
Mercatanti, S. Hammond, and G. Rainaldi. 2006. MicroRNAs modulate the 
angiogenic properties of HUVECs. Blood 108:3068-71. 
51. Rao, D. D., N. Senzer, M. A. Cleary, and J. Nemunaitis. 2009. Comparative 
assessment of siRNA and shRNA off target effects: what is slowing clinical 
development. Cancer Gene Ther 16:807-9. 
52. Roesli, C., V. Mumprecht, D. Neri, and M. Detmar. 2008. Identification of the 
surface-accessible, lineage-specific vascular proteome by two-dimensional peptide 
mapping. Faseb J 22:1933-44. 
53. Shan, S. W., D. Y. Lee, Z. Deng, T. Shatseva, Z. Jeyapalan, W. W. Du, Y. Zhang, 
J. W. Xuan, S. P. Yee, V. Siragam, and B. B. Yang. 2009. MicroRNA MiR-17 
retards tissue growth and represses fibronectin expression. Nat Cell Biol 11:1031-8. 
54. Shin, J. W., R. Huggenberger, and M. Detmar. 2008. Transcriptional profiling of 
VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-
specific molecule-1 as a novel mediator of lymphangiogenesis. Blood 112:2318-26. 
55. Smyth, G. K. 2004. Linear models and empirical bayes methods for assessing 
differential expression in microarray experiments. Stat Appl Genet Mol Biol 
3:Article3. 
56. Srinivasan, R. S., M. E. Dillard, O. V. Lagutin, F. J. Lin, S. Tsai, M. J. Tsai, I. 
M. Samokhvalov, and G. Oliver. 2007. Lineage tracing demonstrates the venous 
origin of the mammalian lymphatic vasculature. Genes Dev 21:2422-32. 
57. Steffensen, K. R., E. Holter, A. Bavner, M. Nilsson, M. Pelto-Huikko, S. 
Tomarev, and E. Treuter. 2004. Functional conservation of interactions between a 
homeodomain cofactor and a mammalian FTZ-F1 homologue. EMBO Rep 5:613-9. 
58. Suarez, Y., C. Fernandez-Hernando, J. S. Pober, and W. C. Sessa. 2007. Dicer 
dependent microRNAs regulate gene expression and functions in human endothelial 
cells. Circ Res 100:1164-73. 
59. Suarez, Y., and W. C. Sessa. 2009. MicroRNAs as novel regulators of angiogenesis. 
Circ Res 104:442-54. 
60. Suarez, Y., C. Wang, T. D. Manes, and J. S. Pober. Cutting edge: TNF-induced 
microRNAs regulate TNF-induced expression of E-selectin and intercellular adhesion 
molecule-1 on human endothelial cells: feedback control of inflammation. J Immunol 
184:21-5. 
61. Thomas, P. D., M. J. Campbell, A. Kejariwal, H. Mi, B. Karlak, R. Daverman, 
K. Diemer, A. Muruganujan, and A. Narechania. 2003. PANTHER: a library of 
protein families and subfamilies indexed by function. Genome Res 13:2129-41. 
62. Thomas, P. D., A. Kejariwal, M. J. Campbell, H. Mi, K. Diemer, N. Guo, I. 
Ladunga, B. Ulitsky-Lazareva, A. Muruganujan, S. Rabkin, J. A. Vandergriff, 
and O. Doremieux. 2003. PANTHER: a browsable database of gene products 
organized by biological function, using curated protein family and subfamily 
classification. Nucleic Acids Res 31:334-41. 
63. Valastyan, S., N. Benaich, A. Chang, F. Reinhardt, and R. A. Weinberg. 2009. 
Concomitant suppression of three target genes can explain the impact of a microRNA 
on metastasis. Genes Dev 23:2592-7. 
64. Valastyan, S., F. Reinhardt, N. Benaich, D. Calogrias, A. M. Szasz, Z. C. Wang, 
J. E. Brock, A. L. Richardson, and R. A. Weinberg. 2009. A pleiotropically acting 
microRNA, miR-31, inhibits breast cancer metastasis. Cell 137:1032-46. 
65. Wigle, J. T., N. Harvey, M. Detmar, I. Lagutina, G. Grosveld, M. D. Gunn, D. G. 
Jackson, and G. Oliver. 2002. An essential role for Prox1 in the induction of the 
lymphatic endothelial cell phenotype. Embo J 21:1505-13. 
66. Yang, W. J., D. D. Yang, S. Na, G. E. Sandusky, Q. Zhang, and G. Zhao. 2005. 
Dicer is required for embryonic angiogenesis during mouse development. J Biol 
Chem 280:9330-5. 
67. Yaniv, K., S. Isogai, D. Castranova, L. Dye, J. Hitomi, and B. M. Weinstein. 
2006. Live imaging of lymphatic development in the zebrafish. Nat Med 12:711-6. 
 at Universitaet Zuerich on M
ay 19, 2010 
m
cb.asm
.org
D
ow
nloaded from
 
 33 
68. Zhao, Y., and D. Srivastava. 2007. A developmental view of microRNA function. 
Trends Biochem Sci 32:189-97. 
 at Universitaet Zuerich on M
ay 19, 2010 
m
cb.asm
.org
D
ow
nloaded from
 
 34 
Table 1: Candidate Endothelial Cell Signature miRNAs 
LEC-Signature miRNAs 
miRNA LEC CtAve BVECAve ∆Ct(LEC/BVEC) Fold Change P-value 
miR-95 30.1112 34.2214 -4.1103 17.2707 0.0180 
miR-326 30.1625 33.6228 -3.4604 11.0073 0.0282 
miR-139 27.8547 31.1069 -3.2522 9.5279 0.2540 
miR-338 30.8759 33.2500 -2.3741 5.1839 0.4161 
miR-148a 29.4379 31.6216 -2.1837 4.5431 0.1488 
miR-30d 25.5822 27.5150 -1.9327 3.8178 0.0630 
miR-15a 27.0135 28.9385 -1.9250 3.7974 0.3196 
miR-324-5p 27.3890 29.1805 -1.7916 3.4619 0.3356 
miR-195 27.5251 29.3149 -1.7898 3.4578 0.2084 
miR-210 28.9097 30.2557 -1.3460 2.5421 0.4663 
miR-30b 23.9905 25.3161 -1.3256 2.5063 0.0703 
miR-26a 23.7606 25.0258 -1.2653 2.4037 0.1753 
miR-222 24.9780 26.1602 -1.1822 2.2692 0.6729 
miR-328 29.1031 30.2401 -1.1370 2.1993 0.4678 
miR-224 27.5416 28.6679 -1.1264 2.1831 0.2294 
miR-197 28.2175 29.3430 -1.1255 2.1818 0.4302 
      
BVEC-Signature miRNAs 
miRNA LEC CtAve BVECAve ∆Ct(LEC/BVEC) Fold Change P-value 
miR-137 33.9680 27.0932 6.8748 117.3599 0.0499 
miR-31 30.9381 24.4353 6.5028 90.6854 0.0132 
miR-335 35.1969 29.6609 5.5360 46.3991 0.0678 
miR-145 34.1980 29.9455 4.2526 19.0610 0.1008 
miR-199-s 32.6853 29.0765 3.6088 12.2003 0.1817 
miR-199b 35.1020 31.5011 3.6009 12.1332 0.1103 
miR-337 35.1329 31.6299 3.5030 11.3371 0.1647 
miR-199a 33.6226 30.3428 3.2797 9.7119 0.1828 
miR-149 33.5595 30.4338 3.1257 8.7281 0.0749 
miR-200a 35.3936 32.3791 3.0145 8.0806 0.1865 
miR-155 29.9803 27.0698 2.9105 7.5189 0.1499 
miR-214 30.1837 27.7623 2.4214 5.3568 0.1725 
miR-124a 34.5812 32.3858 2.1954 4.5800 0.2800 
miR-100 25.2926 23.1597 2.1330 4.3862 0.0700 
miR-215 34.0083 31.9387 2.0697 4.1979 0.4232 
miR-199a* 29.4214 27.5051 1.9162 3.7744 0.3203 
miR-125b 25.7621 23.8861 1.8760 3.6704 0.0410 
miR-221 24.7025 22.8348 1.8677 3.6494 0.1726 
miR-99a 25.1530 23.3489 1.8042 3.4923 0.0340 
miR-216 32.3025 30.5449 1.7576 3.3814 0.1716 
miR-296 33.4409 31.8144 1.6266 3.0877 0.1476 
miR-181a 25.9327 24.4098 1.5229 2.8737 0.3239 
miR-181b 25.4761 23.9781 1.4980 2.8246 0.1783 
miR-154* 29.4587 28.1490 1.3097 2.4789 0.2216 
miR-127 27.1013 25.8016 1.2997 2.4617 0.1863 
miR-181c 30.4691 29.1879 1.2812 2.4304 0.3365 
let-7i 26.6383 25.5251 1.1132 2.1633 0.3326 
miR-134 28.6564 27.5544 1.1019 2.1464 0.1085 
miR-194 32.0133 30.9422 1.0711 2.1010 0.1717 
miR-27a 25.3912 24.3335 1.0577 2.0816 0.3821 
16 candidate LEC-signature miRNAs and 30 BVEC-signature miRNAs were identified 
among the 157 human miRNAs profile in primary human LECs and BVECs based on a > 2-
fold difference in relative expression between endothelial cell types. let-7a/miR-16 
normalized average LEC (LEC CtAve) and BVEC (BVEC CtAve) Ct values, the corresponding 
relative differences (∆CtLEC/BVEC) and absolute fold changes are shown. P-values were 
calculated using a two-tailed Student’s t-test. 
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Table 2: Analysis of Xenopus embryos injected with Pre-miR-31 and Pre-miR-Neg. 
Treatment 
Survival 
At Stage 
39-40 (%) 
ISH 
Marker n 
# Embryos 
Analyzed 
Embryos with Normal 
Vasculature (%) 
Embryos with 
Vascular Defects (%) 
1ng Pre-miR-Neg 84 prox1 61 60 91.7 8.3 
 
 vegfr3 55 52 94.1 5.9 
  
  pecam1 41 23 95.7 4.3 
10ng Pre-miR-Neg 84 prox1 48 46 91.3 8.7 
 
 vegfr3 59 57 94.7 5.3 
  
  pecam1 49 44 100 0.0 
100ng Pre-miR-Neg 79 prox1 21 21 95.2 4.8 
 
 vegfr3 19 19 78.9 21.1 
  
  pecam1 16 15 73.3 26.7 
1ng Pre-miR-31 74 prox1 70 68 94.1 5.9 
 
 vegfr3 89 82 93.9 6.1 
  
  pecam1 64 63 100.0 0.0 
10ng Pre-miR-31 57 prox1 50 48 93.8 6.3 
 
 vegfr3 60 56 87.5 12.5 
  
  pecam1 35 29 86.2 13.8 
25ng Pre-miR-31 66 prox1 36 31 64.5 35.5 
 
 vegfr3 34 31 64.5 35.5 
  
  pecam1 37 29 55.2 44.8 
50ng Pre-miR-31 52 prox1 34 29 48.3 51.7 
 
 vegfr3 31 21 23.8 76.2 
  
  pecam1 32 25 24.0 76.0 
Lymphatic and blood vascular development was monitored by whole mount in situ 
hybridization of embryos microinjected with Pre-miR-31 and Pre-miR-Neg. The number and 
frequency of lymphatic and blood vascular developmental defects, as scored based on the 
presence of several lymphatic and blood vascular structures, are presented. 
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Table 3: Analysis of zebrafish embryos injected with Pre-miR-31 and Pre-miR-Neg. 
 
Treatment 
Relative number 
of venous sprouts SD n p-value 
% of 
UIC 
UIC 1.000 0.348 120  100 
Pre-miR-Neg 340 pg 1.391 0.477 71 6.32688E-10 139 
Pre-miR31 170 pg 0.306 0.170 24 6.20522E-17 31 
Pre-miR31 340 pg 0.140 0.175 46 2.86825E-35 14 
Venous sprouting was monitored in TG(fli1a:gfp)y1:plcg1t26480 mutant zebrafish embryos 
injected with Pre-miR-31 and Pre-miR-Neg by fluorescence confocal microscopy. The 
number of venous sprouts were normalized to the UICs and represented as relative numbers 
of venous sprouts. 
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Figure Legends 
Figure 1: Identification of vascular lineage-specific miRNAs. qRT-PCR using individual 
TaqMan miRNA Assays confirmed the lymphatic-specific expression of miR-95 and miR-
326 (A), and the BVEC-specific expression of miR-137, miR-31, miR-125b and miR-99a (B). 
Data were normalized using RNU48 and are shown as mean relative abundances +/- SD 
(n=4/group). * p ≤ 0.05.  
Figure 2: miR-31 is preferentially expressed by BVECs in vivo. (A) Mouse BVECs (CD45–
CD31+podoplanin–) and LECs (CD45–CD31+podoplanin+) were isolated from adult mouse 
colons (n=8) by FACS sorting. TaqMan qRT-PCR analysis of mmu-miR-31 demonstrated 
that miR-31 was at least 1.5-fold more abundant in BVECs from 6 of the 8 mice. Data were 
normalized using sno234 and are shown as relative abundances +/- SD.  * p ≤ 0.05; **  p ≤ 
0.01; ***  p ≤ 0.001; ns, not statistically significant. (B-I) miR-31 (B, D and F), negative 
control (G; sense-miR-159) ISH and double immunofluorescence (C, E, H and I) of serial 
sections of adult mouse colon tissues imaged at low magnification (2.5x; B-E) and high 
magnification (20x; F-I). Low magnification of ISH of adult mouse colon revealed strong 
miR-31 staining in the majority of the cells (B and D), while double immunofluorescence 
analysis of serial sections (C and E), and comparison of miR-31 and sense-miR-159 probed 
sections at high magnification (F-I), demonstrated that miR-31 preferentially co-localized 
with blood vessels (CD31+LYVE1-) present in the submucosa and mesenteric attachments of 
the colon (arrows), as well as the lamina propria (arrowheads). In contrast, lymphatic vessels 
(CD31+LYVE1+) displayed weak or no miR-31 signals (asterisks).  Panels F and G are high 
magnification images of the boxed regions in panels D and E, respectively. Corresponding 
blood and lymphatic vessels in panels F-I are numbered. Scale bars = 200 µm (B-E) and 50 
µm (F-I). 
Figure 3: miR-31 overexpression in LECs modulates the expression of BVEC- and LEC-
signature genes. (A-B) miR-31 was overexpressed in LECs via transfection with 2µM Pre-
miR-31 precursor (n=2) or Pre-miR-Neg (n=2). Microarray analysis after 48 hours 
demonstrated that miR-31 overexpression repressed the expression of 33 LEC-signature 
genes (A) and 23 BVEC-signature genes (B). In addition, 4 LEC-signature genes and 22 
BVEC-signature genes were induced. (C-E) TaqMan-based qRT-PCR analyses confirmed 
statistically significant miR-31-mediated repression of 4 of the LEC-signature genes studied 
(C) and of 2 of the BVEC-signature genes studied (D), as well as statistically significant 
induction of 2 of the BVEC-signature genes studied (E). Data were normalized using β-actin  
and are shown as relative abundances +/- SD. * p ≤ 0.05; **  p ≤ 0.01; ***  p ≤ 0.001). 
Figure 4: miR-31 gain-of and loss-of function modulates PROX1 mRNA and protein levels. 
(A-C)  Transfection of LECs with 4 µM Pre-miR-31 precursor (n=4) or Pre-miR-Neg (n=4). 
(A) qRT-PCR analysis revealed a ≥60% decrease in PROX1 transcripts after 48 hours. (B) 
Immunoblotting of cell lysates with α-PROX1 and α-β-actin antibodies (loading control) 
demonstrated decreased PROX1 protein levels following miR-31 gain-of-function. (C) Semi-
quantivative analysis of PROX1 immunoblot signal intensities, relative to β-actin, defined an 
<40% reduction of PROX1 protein following miR-31 overexpression. Data are shown as 
relative abundances +/- SD (n=4/group). (D) qRT-PCR analysis showed that transfection of 
HUVECs with 4 µM Anti-miR-31 inhibitor (n=2) or Anti-miR-Neg (n=2) induced a ≥1.69-
fold increase in PROX1 mRNA levels after 48 hours. Data were normalized using β-actin and 
are shown as mean relative abundances +/- SD. ***  p ≤ 0.001). 
Figure 5:  Direct post-transcriptional regulation of PROX1 by miR-31. (A)  Schematic 
representation of the full-length PROX1 3’UTR and the consecutive fragments present in the 
PROX1 3’UTR-luciferase reporter constructs (PROX1 FL-F6). Candidate miR-31 binding 
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sites identified using standard nucleic acid alignment techniques (gray) and TargetScan 5.0 
(black) are indicated. The PROX1:miR-31 base-pairing is shown for the 7mer-m8 TargetScan 
predicted binding site. (B-D) LECs or HUVECs were co-transfected with the plasmids 
containing a miR-31 binding site (miR-31BS), the PROX1 3’UTR (FL-F6), the PROX1 
coding sequence (CDS), or PROX1 3’UTR miR-31 binding site mutants (FLmut or F2mut) 
and Pre-miR-31 precursor, Anti-miR-31 inhibitor or negative control molecules. (B) The 
activities of luciferase constructs containing miR-31BS, PROX1 FL and PROX1 F2 
decreased significantly following miR-31 overexpression (Pre-miR-31; n=3) in LECs 
compared to negative controls (Pre-miR-Neg; n=3). (C) miR-31BS and PROX1 FL reporter 
gene activities increased significantly following miR-31 inhibition (Anti-miR-31; n=3) in 
HUVECs compared to negative controls (Anti-miR-Neg; n=3). miR-31 loss-of-function also 
enhanced the activities of PROX1 F1 and PROX1 F2 constructs, but these differences were 
not statistically significant. (D) miR-31 mutant binding site full-length and F2 PROX1 3’UTR 
(PROX1 FLmut and PROX1 F2mut) luciferase activities showed no major change following 
miR-31 overexpression (Pre-miR-31, n=3) or knockdown (Anti-miR-31, n=3). Data were 
normalized to firefly luciferase activities and are shown as mean relative abundances +/- SE. 
ns, not significant; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001). 
Figure 6:  miR-31 overexpression in Xenopus impairs lymphatic vessel sprouting from the 
lymph heart. 2-cell stage Xenopus embryos were co-injected with Pre-miR-31 precursor (50 
ng) or Pre-miR-Neg (100 ng) control molecules and 0.2 ng of β-gal mRNA (lineage tracer) 
and were raised to stage 39. (A-B) Lymphatic vascular system development was monitored by 
whole-mount ISH for prox1 (A) and vegfr3 (B). Pre-miR-31 injected embryos exhibited 
marked defects in lymphatic vascular development, the most striking of which was impaired 
lymphatic vessel sprouting (arrowheads) from the lymph heart (arrow). (C) Pecam1 ISH 
showed that intersomitic vein growth (arrowheads) was unilaterally misguided or delayed in 
embryos with elevated levels of miR-31. 
Figure 7: miR-31 overexpression decreases venous sprouting in zebrafish embryos. (A) 
plcg1t26480 mutant embryos in the TG(fli1a:gfp)y1 background were injected with 340 pg of 
negative control Pre-miR-Neg (n=71) or 340 pg (n=46) or 170 pg (n=24) of human Pre-miR-
31 precursor. Venous sprouts were quantified at 48 hpf. UIC, uninjected control (n=120). 
Data are shown as mean +/- SD relative to the UIC of the same clutch. *** p ≤ 0.001. (B-F) 
Lateral views of plcg1t26480 mutant embryos in TG(fli1a:gfp)y1 background. Dorsal aorta 
formation and sprouting of intersegmental arteries is suppressed in mutant embryos and 
therefore only venous sprouts (examples indicated with arrows) and parachordal 
lymphangioblasts (asterisks) are visible in the dorsal trunk. Uninjected control plcg1t26480 
mutant embryo (B) and plcg1t26480 mutant embryos injected with 340 pg negative control Pre-
miR-Neg (C) or 340 pg human Pre-miR-31 precursor (D) at day 2 postfertilization. PCV, 
posterior cardinal vein. 
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